MX2009011843A - Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible. - Google Patents

Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.

Info

Publication number
MX2009011843A
MX2009011843A MX2009011843A MX2009011843A MX2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A
Authority
MX
Mexico
Prior art keywords
reversible
intravenous
inhibitor
acting
direct
Prior art date
Application number
MX2009011843A
Other languages
English (en)
Spanish (es)
Inventor
Anjali Pandey
Pamela B Conley
Patrick Andre
Daniel D Gretler
Athiwat Hutchaleelaha
David R Phillips
Huang Wolin
Robert M Scarborough
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2009011843A publication Critical patent/MX2009011843A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009011843A 2007-05-02 2008-05-02 Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible. MX2009011843A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
MX2009011843A true MX2009011843A (es) 2010-04-22

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011843A MX2009011843A (es) 2007-05-02 2008-05-02 Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.

Country Status (17)

Country Link
US (2) US20090048216A1 (enExample)
EP (1) EP2079464A2 (enExample)
JP (1) JP2010526101A (enExample)
KR (1) KR20100029746A (enExample)
CN (1) CN101795682A (enExample)
AU (1) AU2008247483A1 (enExample)
BR (1) BRPI0811476A2 (enExample)
CA (1) CA2686203A1 (enExample)
CO (1) CO6241104A2 (enExample)
EA (1) EA200901473A1 (enExample)
EC (1) ECSP099778A (enExample)
GT (1) GT200900284A (enExample)
IL (1) IL201834A0 (enExample)
MA (1) MA31663B1 (enExample)
MX (1) MX2009011843A (enExample)
TN (1) TN2009000451A1 (enExample)
WO (1) WO2008137753A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006311795B2 (en) * 2005-11-03 2013-01-17 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
MX2009009492A (es) * 2007-03-06 2009-09-15 Novartis Ag Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
KR20100020455A (ko) * 2007-05-02 2010-02-22 포톨라 파마슈티컬스, 인코포레이티드 상이한 결정질 형태의 [4-(6-플루오로-7-메틸아미노-2,4-디옥소-1,4-디히드로-2ｈ-퀴나졸린-3-일)-페닐]-5-클로로-티오펜-2-일-술포닐우레아염, 및 이의 제약 조성물
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2384196B1 (en) * 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
SI2498731T1 (sl) 2009-11-11 2020-05-29 Chiesi Farmaceutici S.P.A. Postopki zdravljenja ali preprečevanja tromboze stenta
EP2515871B1 (en) * 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072743A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
WO2012072824A1 (en) * 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
UA125531C2 (uk) 2017-03-15 2022-04-13 Ідорсія Фармасьютікалз Лтд ПІДШКІРНЕ ВВЕДЕННЯ АНТАГОНІСТА P2Y<sub>12</sub> РЕЦЕПТОРА
EP3641784A1 (en) 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
AU2006311795B2 (en) 2005-11-03 2013-01-17 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Also Published As

Publication number Publication date
JP2010526101A (ja) 2010-07-29
CO6241104A2 (es) 2011-01-20
US20090048216A1 (en) 2009-02-19
WO2008137753A3 (en) 2009-02-12
GT200900284A (es) 2012-01-31
AU2008247483A1 (en) 2008-11-13
MA31663B1 (fr) 2010-09-01
CN101795682A (zh) 2010-08-04
ECSP099778A (es) 2010-01-29
BRPI0811476A2 (pt) 2014-11-04
WO2008137753A2 (en) 2008-11-13
CA2686203A1 (en) 2008-11-13
IL201834A0 (en) 2010-06-16
TN2009000451A1 (en) 2011-03-31
US20120009172A1 (en) 2012-01-12
KR20100029746A (ko) 2010-03-17
EP2079464A2 (en) 2009-07-22
EA200901473A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
MX2009011843A (es) Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.
ECSP099376A (es) Inhibidores de la actividad de la akt
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
IL211825A (en) Compounds based on pyridine and pyrimidine for use as wnt signal transducer inhibitors, pharmaceutical formulations containing such compounds and used as drugs for the treatment and / or cancer prevention
HRP20110451T1 (hr) Upotreba izotiocijanata kao sredstva protiv mieloma
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
ECSP077980A (es) Inhibidores de la actividad akt
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
MY162146A (en) Pharmaceutical composition
PH12014500386A1 (en) Combination treatment for hepatitis c
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EP2137175A4 (en) NOVEL PHENANTHRENNEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF METABOLIC SYNDROME INVOLVING DISEASES
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
IN2012DN03428A (enExample)
PH12013500695A1 (en) Pharmaceutical compositions containing a dgat1 inhibitor
MX2010005714A (es) Compuestos de piridina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal